Big Law

Amgen Wins Appeal in Patent Case Over Generic Versions of Psoriasis Drug

Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.

The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court’s ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.

The Federal Circuit also upheld a decision to invalidate one of Amgen’s patents that Sandoz said would have barred its generics until 2034.

Read the source article at finance.yahoo.com

Back to top button